In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Oncology powerhouse Roche has reported positive results from the Phase III ALINA study of Alecensa (alectinib). 1 September 2023
Pharmaceutical
Japanese mid-size drugmaker Otsuka Pharmaceuticals has entered into a definitive arrangement agreement to acquire Toronto, Canada-based Mindset Pharma. 1 September 2023
Pharmaceutical
Despite a narrow focus on drug spending, roughly 30% of every dollar spent on health care in the USA can be attributed to hospitals. 1 September 2023
Biotechnology
US synthetic DNA producer Twist Bioscience today announced a drug discovery agreement with Japan’s Ono Pharmaceutical to discover and develop novel antibodies for the treatment of autoimmune diseases. 31 August 2023
Biotechnology
Enhertu (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy designations (BTDs) in the USA. 31 August 2023
Pharmaceutical
Privately-held Danish company MC2 Therapeutics today announced an agreement under which a Huadong Medicine unit has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream for the treatment of plaque psoriasis. 31 August 2023
Pharmaceutical
French drugmaker Sanofi has made a series of changes to its executive team, including the appointment of a new head of research and development. 31 August 2023
Biotechnology
US ophthalmology focused biotech Outlook Therapeutics saw its shares closed down more than 80% at $0.27 yesterday, after it revealed that the US Food and Drug Administration (FDA) has issued a CRL to the company’s biologic license application (BLA) for ONS-5010. 31 August 2023
Biotechnology
US biotech BioMarin Pharmaceutical late yesterday announced that an individual in Germany with severe hemophilia A was treated with Roctavian (valoctocogene roxaparvovec-rvox), marking the first time that the gene therapy has been given commercially in Europe. 31 August 2023
Biotechnology
Research from industry analyst GlobalData suggests that German company BioNTech will likely be a leader in the emerging market for mRNA-based oncology therapies. 31 August 2023
Biotechnology
An Expert View from Luigi Angelillo and Cecile can Steen from Santen, and Kirsty Ross-Stewart, Justus Dehnen and Walter Colasante from the global consulting firm CRA. 31 August 2023
Biotechnology
The diabetic macular edema (DME) market in the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow from $5.4 billion in 2021 to $9.6 billion in 2031. 31 August 2023
Pharmaceutical
US pharma giant Merck & Co, known as MSD outside of the USA and Canada, will stop deliveries to Russia of Zepatier (elbasvir/grazoprevir), one of the most popular drugs against hepatitis C, reports The Pharma Letter’s local correspondent. 30 August 2023
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended authorizing a version of BioNTech and Pfizer’s Comirnaty COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant. 30 August 2023
Generics
In a major reprieve, India's National Medical Commission (NMC) has put on hold with immediate effect its recent regulation mandating doctors to prescribe only generic drugs or face strict punishment. 30 August 2023
Pharmaceutical
In a bid to consolidate its lead in the weight management therapy sector, diabetes care giant Novo Nordisk has now bought a fellow Denmark based company and its obesity program. 30 August 2023
Biotechnology
US biopharma Apellis has announced a company restructuring in a bid to focus on making Syfovre (pegcetacoplan injection) a leading treatment for geographic atrophy (GA). 30 August 2023
Generics
Russian drugmaker R-Pharm is considering acquiring the manufacturing facility of Japanese pharma giant Takeda located in Yaroslavl, Russia, The Pharma Letters local correspondent reports. 30 August 2023
Biotechnology
Shares of US biotech FibroGen were down 22% at $0.995 pre-market today, after it announced top-line data from the Phase III LELANTOS-2 trial of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD) on background systemic corticosteroids. 30 August 2023
Pharmaceutical
Japanese drugmaker Kyowa Kirin has received approval in its home country for a higher-dose formulation of its oral calcimimetics agent Orkedia (evocalcet). 30 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze